膀胱移行细胞癌中p53、nm23和bcl-2的表达及临床意义  

Expressions of p53, nm23, bcl-2 in Bladder Transitional Cell Carcinoma and Its Clinical Significance

作　　者：李怀富[1] 郑巍[1] 殷放[1] 郑浩[1] 郑小青[1] 郭德荣[1] 詹鸣[1] 

机构地区：[1]中山大学附属第五医院泌尿外科,519000

出　　处：《中国临床实用医学》2010年第7期59-61,共3页China Clinical Practical Medicine

摘　　要：目的探讨膀胱移行细胞癌组织中p53、nm23和bcl-2的表达及临床意义。方法应用免疫组织化学ABC方法，检测60例膀胱移行细胞癌中p53、nm23和bcl-2的表达情况。结果60例膀胱移行细胞癌组织中，p53阳性率48．3％，nm23的阳I眭率50．0％，bcl-2的阳性率55．0％，p53、nm23和bcl-2的表达与膀胱移行细胞癌的病理分级和临床分期显著相关（P〈0．05）。结论p53、nm23和bcl-2的表达，提示膀胱移行细胞癌预后不良，可以作为评价膀胱癌患者预后的指标。Objective To investigate the expression of p53, nm23, bel-2 in bladder transitional cell carcinoma（BTCC） and its clinical significance. Methods The expressions of p53, nm23, bcl-2 was detected using immunohistochemical ABC method in 60 patients with BTCC. Results The positive rates of p53, nm23, bcl-2 in the 60 cases of BTCC tissue were 48. 3% ,50.0% and 55.0% ,respectively. The expression of p53 ,bcl- 2, nm23 were correlated closely with the pathological grade and clinical stage of BTCC （P 〈 0. 05 ）. Conclusion The expressions of p53, bcl-2, nm23 predict unfavourable prognosis of BTCC, and can be a marker that is used to evaluate patients＇ prognosis.

关 键 词：膀胱肿瘤 P53 NM23 BCL-2 预后 

分 类 号：R737.14[医药卫生—肿瘤]